StockNews.AISignal intelligence
CareDx, Inc · NASDAQ · Healthcare
Browse public CDNA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
CareDx has finalized the sale of its Lab Products division to focus on core Testing Services, which saw robust year-over-year growth. This transaction, which brings $170 million in cash and aims to enhance capital allocation, could bolster long-term growth initiatives and shareholder returns.
View signal analysisCareDx expects Q3 revenue of $82M-$83M, up 23% year-over-year. CDNA shares fell 9% to $28.50 in pre-market trading. U.S. stock futures slightly gained; overall market sentiment mixed. Other stocks also faced declines in pre-market trading sessions.
View signal analysis- CDNA reported revenue of $72.05 million, down 6.7% over the same period last year. - EPS came in at -$0.03, compared to -$0.11 in the year-ago quarter. - Revenue from patient and digital solutions increased by 11.6% year over year. - Price Impact Rating: bearish - Impact Horizon Rating: short-term - Type: Earnings
View signal analysis- Expected quarterly loss of $0.19 per share, 72.7% decline from last year. - Revenue forecast of $63.63 million, down 17.7% year over year. - Consensus EPS estimate unchanged in the last 30 days. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis